Insider Buying: Roquefort Therapeutics (LON:ROQ) Insider Purchases £8,500,000 in Stock

Roquefort Therapeutics plc (LON:ROQ) insider Dr Darrin Disley bought 5,000,000 shares of the company’s stock in a transaction on Friday, November 21st. The shares were acquired at an average cost of GBX 170 per share, for a total transaction of £8,500,000.

Roquefort Therapeutics Stock Up 11.0%

Shares of Roquefort Therapeutics stock opened at GBX 1.97 on Thursday. The stock has a market capitalization of £3.10 million, a price-to-earnings ratio of -3.13 and a beta of 0.05. Roquefort Therapeutics plc has a twelve month low of GBX 1.08 and a twelve month high of GBX 5.50. The company has a current ratio of 0.79, a quick ratio of 3.07 and a debt-to-equity ratio of 12.37. The business’s 50 day simple moving average is GBX 1.92 and its 200-day simple moving average is GBX 1.71.

Roquefort Therapeutics (LON:ROQ) last released its quarterly earnings data on Tuesday, September 30th. The company reported GBX (0.33) earnings per share (EPS) for the quarter. Roquefort Therapeutics had a negative net margin of 57,057.07% and a negative return on equity of 29.57%.

Roquefort Therapeutics Company Profile

Roquefort Therapeutics is a LSE Main Market listed biotech company developing first in class drugs in the high value and high growth oncology segment prior to partnering or selling to big pharma. Since listing in March 2021, Roquefort Therapeutics has successfully acquired Lyramid Pty Limited, a leader in the development of medicines for a new therapeutic target, Midkine (a human growth factor associated with cancer progression), and most recently acquired Oncogeni Ltd, founded by Nobel Laureate Professor Sir Martin Evans, which has developed two families of innovative cell and RNA oncology medicines.